ALZHEIMER’S DISEASE: NEW DIAGNOSTIC CRITERIA AND THERAPEUTIC ASPECTS DEPENDING ON THE STAGE OF THE DISEASE
https://doi.org/10.21518/2079-701X-2017-10-18-24
Abstract
The new criteria for diagnosing Alzheimer’s disease (AD) proposed by the United States National Aging Institute and the Alzheimer Association are being discussed. The definition of the preclinical and pre-dementing stages of AD has been introduced. The current issues of diagnostics of the pathophysiological process in AD with the use of biological markers and modern neurovisualization methods, approaches to treatment of AD depending on the stage of the disease are considered. The effectiveness of Memantine (akatynol memantine) and its usefulness at the various stages of disease in patients with AD is noted. Nonpharmacological methods of AD therapy, including cognitive training, behavioural and psychosocial methods, are considered.
About the Author
N. N. Koberskaya
Sechenov First Moscow State University of the Ministry of Health of Russia
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
References
1. Васенина Е.Е., Левин О.С. Дифференциальный подход к диагностике и терапии деменции. Consilium Medicum, 2016, 2: 71-74.
2. Коберская Н.Н. Клинические, диагностические и терапевтические аспекты умеренных когнитивных нарушений амнестического типа. Медицинский Совет, 2015, 5: 40-45.
3. Международная статистическая классификация болезней и проблем, связанных со здоровьем. Десятый пересмотр. (МКБ-10). Т.1 (часть 1). Женева: ВОЗ, 1995. С. 315, 510-511.
4. Парфенов В.А., Захаров В.В., Преображенская И.С. Когнитивные расстройства. М.: Ремедиум, 2014.
5. Парфенов В.А. Ранняя диагностика и лечение болезни Альцгеймера. Медицинский совет, 2015, 5: 28-33.
6. Яхно Н.Н., Захаров В.В., Локшина А.Б. и др. Деменции: рук-во для врачей. 3-е изд. М.: МЕДпресс-информ, 2011, 272 с.
7. Albert MS, Dekosky ST, Dickson D et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging and Alzheimer’s Association workgroup. Alzheimers Dement, 2011, 5: 270-279.
8. Alzheimer’s Disease International. World Alzheimer report 2013. www.alz.co.uk/research/world-report-2013.
9. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington: American Psychiatric Association, 1994.
10. Atri A et al. Memantine in patients with Alzheimer’s disease receiving donepezil: new analyses of efficacy and safety for combination therapy. Alzheimer’s Res. & Therapy, 2013, 5(6): 1-11.
11. Bennett DA, Schneider J.A., Arvanitakis Z. et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology, 2006; 66(12): 1837-44.
12. Chertkow H, Feldman HH, Jcova C et al. Definitions of dementia and predementia states in Alzheimer’s disease and vascular cognitive impairment: consensus from the Canadian conference on diagnosis of dementia. Alzheimers Res Ther, 2013, 5(Suppl 1).
13. Cummings J, Aisen P, DuBois B. Drug development in Alzheimer’s disease: the path to 2025. Alzheimer’s Research & Therapy, 2016, 8: 39.
14. Dubois B, Feldman H et al. Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol, 2010, 5: 1118-1127.
15. Godyn J, Jonczyk J et al. Therapeutic strategies for Alzheimer’s disease in clinical trials. Pharmacological Reports, 2016, 68(1): 127-138.
16. Harper L, Fumagalli GG, Barkhof F. MRI visual rating scales in the diagnosis of dementia: evaluation in 184 post-mortem confirmed cases. Brain, 2016, 139: 1211-1225.
17. Hsu DC, Marshall GA. Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving . Curr Alzheimer Res, 2017, 14(4): 426-440.
18. Jack CR, Albert MS, Knopman DS et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheim. Dement., 2011, 7(3): 257-62.
19. Jack CR, Lowe VJ et al. Alzheimer’s Disease Neuroimaging Initiative. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer’s disease: implications for sequence of pathological events in Alzheimer’s disease. Brain, 2009, 5: 1355-1365.
20. Jack CR, Knopman DS et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol, 2010, 5: 119-128.
21. Katzman R. Education and prevalence of dementia and Alzheimer’s disease. Neurology, 1993, 43: 13-20.
22. McKhann GM, Knopman DS, Chertkow H et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging and the Alzheimer’s Association workgroup. Alzheimers Dement, 2011, 5: 263-269.
23. McKhann G, Drachman D, Folstein M et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology, 1984, 34: 939-944.
24. Mendiola-Precoma J, Berumen LC, Padilla K. Therapies for Prevention and Treatment of Alzheimer’s Disease. BioMed Research International, 2016: 17.
25. Mintun MA, Larossa GN, Sheline YI et al. PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology, 2006, 5: 446-452.
26. Morris JC, Storandt M et al. Cerebral amyloid deposition and diffuse plaques in ‘normal’ aging: evidence for presymptomatic and very mild Alzheimer’s disease. Neurology, 1996, 5: 707-719.
27. Petersen RC. Mild cognitive impairment. J. int. med, 2004, 256(3): 183-194.
28. Petersen KA. Compliance and practical considerations in the management of Alzheimer’s disease with memantine. Eur J Neurology, 2007, 14(1): 1107.
29. Peskind ER, Potkin SG, Pomara N et al. Memantine treatment in mild to moderate Alzheimer’s disease. Am J Geriatr Psychiatry, 2006, 14: 704-15.
30. Porsteinsson A, Grossberg G, Mintzer J, Olin J. Memantine treatment in patients with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res, 2008, 5(1): 83-89.
31. Racine AM, Clark LR, Berman SE et al. Associations between performance on an abbreviated CogState battery, other measures of cognitive function, and biomarkers in people at risk for Alzheimer’s disease. J Alzheimers Dis, 2016 October 18, 54(4): 1395-1408.
32. Reisberg B, Doody R, Stoffler A, Schmitt F et al. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med, 2003, 348: 1333-41.
33. Reisberg B, Doody R, Stoffler A et al. A 24-week open-label extension study of memantine in moderate to severe Alzheimer’s disease. Arch Neurol, 2006, 63: 49-54.
34. Sperling RA, Aisen PS, Beckett LA, Bennett DA, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging and the Alzheimer’s Association workgroup. Alzheimers Dement, 2011, 5: 280-292.
35. Schmidt R, Ropele S, Ebenbauer B et al. Memantine effects on brain volume, glucose metabolism and cognition in AD patients. Eur J Neurology, 2007, 14(1): 2526.
36. Tariot PT, Farlow MR, Grossberg GR et al. Memantine Treatment in Patients With Moderate to Severe Alzheimer Disease Already Receiving Donepezil: A Randomized Controlled Trial. JAMA, 2004, 291: 317-24.
37. Tocco M, Resnick EM, Graham S et al. Cognitive effects of memantine in moderate to severe Alzheimer’s disease: a responder analysis. Eur J Neurology, 2007, 14(1): 1098.
38. Winblad B, Jones R, Wirth Y et al. Memantine in moderate to severe Alzheimer’s disease: metaanalysis of randomized clinical trials. Dement Geriatr Cogn Disord, 2007, 24: 20-7.
Review
For citations:
Koberskaya NN. ALZHEIMER’S DISEASE: NEW DIAGNOSTIC CRITERIA AND THERAPEUTIC ASPECTS DEPENDING ON THE STAGE OF THE DISEASE. Meditsinskiy sovet = Medical Council. 2017;(10):18-24. (In Russ.) https://doi.org/10.21518/2079-701X-2017-10-18-24
Views:
1066
Email this article 